July 23, 2017 8:42 AM ET

Biotechnology

Company Overview of Zenith Epigenetics Corp.

Company Overview

,  

Canada

Key Executives for Zenith Epigenetics Corp.

Chairman, Chief Executive Officer and President
Chief Financial Officer and Secretary
Chief Medical Officer
Senior Vice President of Operations
Chief Business Officer
Compensation as of Fiscal Year 2017.

Zenith Epigenetics Corp. Key Developments

Zenith Epigenetics Corp. Presents at BIO International Conference 2017, Jun-20-2017 03:30 PM

Zenith Epigenetics Corp. Presents at BIO International Conference 2017, Jun-20-2017 03:30 PM. Venue: San Diego Convention Center, San Diego, CA 2865, United States. Speakers: Donald J. McCaffrey, Chairman, Chief Executive Officer and President.

Zenith Epigenetics Corp. Presents at 19th Annual BIO CEO & Investor Conference, Feb-14-2017 11:15 AM

Zenith Epigenetics Corp. Presents at 19th Annual BIO CEO & Investor Conference, Feb-14-2017 11:15 AM. Venue: The Waldorf Astoria New York, 301 Park Avenue, New York, NY 10022, United States. Speakers: Donald J. McCaffrey, Chairman, Chief Executive Officer and President.

Zenith Epigenetics Ltd. Announces Initiation of Phase 1b Clinical Combination Trial for ZEN-3694

Zenith Epigenetics Ltd. has initiated a Phase 1b clinical trial in metastatic Castration Resistant Prostate Cancer (mCRPC) patients, dosing ZEN-3694 in combination with enzalutamide.  In this Phase 1b trial, Zenith Epigenetics will be evaluating the safety, pharmacokinetics, and efficacy of ZEN-3694 in combination with, enzalutamide (Xtandi) in mCRPC patients that have progressed on first-line standard-of-care anti-androgen therapy. The trial will encompass a dose escalation phase and an expansion phase, designed to potentially show early proof-of-concept. The trial also includes a broad translational program, measuring target modulation as well as evaluating potential pharmacodynamic biomarkers for identifying patients who may benefit the most from the combination treatment. Zenith Epigenetics continues to advance its single agent Phase 1 clinical trial with ZEN-3694, working with prominent clinical investigators and the Prostate Cancer Clinical Trial Consortium (PCCTC) who collectively have been instrumental in developing leading drugs for the treatment of mCRPC, including enzalutamide and abiraterone (Xtandi and Zytiga respectively). Zenith Epigenetics has also developed strong pre-clinical rationale for developing ZEN-3694 in other oncology indications which may be explored in future clinical programs.

Similar Private Companies By Industry

Company Name Region
2007262 Ontario, Inc. Americas
2056273 Ontario, Inc. Americas
AB BioPharma Inc. Americas
AbCelex Technologies Inc. Americas
AbCellera Biologics Inc. Americas

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
The Advertising Council, Inc. United States
Bertelsmann AG Europe
Rush University United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Zenith Epigenetics Corp., please visit --. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.